GLP-1 Treatment: What It Involves, Who Qualifies & How to Get Started

GLP-1 treatment is now the most prescribed weight loss therapy in history.

Key Takeaways

• What it is: A prescription drug therapy using GLP-1 receptor agonists — not a diet plan, supplement, or surgical procedure.
• Who qualifies: Adults with a BMI ≥30, or BMI ≥27 with at least one weight-related condition such as type 2 diabetes, hypertension, sleep apnea, dyslipidemia, or cardiovascular disease.
• How it starts: Consultation (in-person or telehealth), baseline labs, prescription, and a slow titration over 16–20 weeks before reaching a maintenance dose.
• Week-by-week reality: Weeks 1–4 feel like little is happening; weeks 4–12 bring noticeable appetite changes; week 12+ is when significant weight loss typically registers.
• It's ongoing: Most clinical guidelines now treat obesity as a chronic condition — GLP-1 treatment manages it the same way a blood pressure medication manages hypertension.
• Honest limitation: Insurance coverage remains inconsistent, and prior authorization battles are common. Access is real but not frictionless.

What most people don't realize is that GLP-1 treatment isn't a program you enroll in and graduate from. It's a medical therapy with a specific mechanism, specific eligibility criteria, and a specific trajectory that unfolds over months — not weeks. If you've been wondering whether you qualify, what the process actually looks like, and what to expect when you start, this guide walks through all of it.

GLP-1 treatment is not a diet.

That distinction matters more than it might seem at first. A diet changes what you eat. A supplement adds something to your routine. A procedure changes your anatomy. GLP-1 treatment does something different: it changes the hormonal signals your brain and gut use to regulate appetite, blood sugar, and metabolism.

GLP-1 stands for glucagon-like peptide-1 — a hormone your small intestine releases after eating. It signals the pancreas to release insulin, slows gastric emptying, and tells the brain that food has arrived. In most people with obesity, this system is blunted. GLP-1 receptor agonists — the drugs used in treatment — amplify that signal dramatically, producing the appetite suppression and metabolic effects that clinical trials have documented for two decades.

The drugs in this class include semaglutide (Ozempic for type 2 diabetes, Wegovy for obesity), tirzepatide (Mounjaro for T2D, Zepbound for obesity), and liraglutide (Saxenda for obesity). Each is a prescription medication. None are available over the counter. Obtaining one begins with a clinical evaluation — which is where treatment actually starts.

Who qualifies for GLP-1 treatment

FDA eligibility criteria are specific and relatively straightforward.

You qualify if you have a BMI of 30 or higher — that is the threshold for obesity by clinical definition. You also qualify if your BMI is 27 or higher and you have at least one weight-related comorbidity. The recognized comorbidities that meet this threshold include type 2 diabetes, hypertension (high blood pressure), obstructive sleep apnea, dyslipidemia (elevated cholesterol or triglycerides), and established cardiovascular disease.

If you fall into either category, you are within the FDA-approved indication for one or more GLP-1 therapies. That does not guarantee insurance coverage, but it means a physician can prescribe these medications to you without prescribing outside their approved use.

A BMI of 27 is often lower than people expect the threshold to be. Someone who is 5'6" and weighs 168 pounds has a BMI of 27.1 — technically in the "overweight" category, not "obese." If that person also has hypertension or prediabetes, they meet the clinical criteria for GLP-1 treatment. The eligibility pool is larger than the public perception of who these drugs are for.

What the treatment process actually involves

The first step is a clinical consultation.

This happens either in-person — with a primary care physician or obesity medicine specialist — or through a telehealth platform. Telehealth has made this step dramatically more accessible: initial consultations can happen the same week you reach out, and the full process from first appointment to prescription in hand can take as few as five business days.

The consultation typically involves a review of your medical history, current medications, and weight history. Your provider will want to rule out conditions that contraindicate GLP-1 therapy. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) are the primary contraindications. Pancreatitis history warrants careful evaluation as well.

Before prescribing, most providers order baseline labs. The standard panel includes a metabolic panel (kidney and liver function, electrolytes, blood glucose), a lipid panel, a thyroid panel (TSH), and an HbA1c to assess average blood sugar over the previous three months. These labs give your provider a metabolic baseline and catch any conditions that should be monitored during treatment.

The titration schedule: patience is the actual requirement

Starting dose does almost nothing on its own.

This surprises many people in the first few weeks of treatment. You inject the starting dose of semaglutide — 0.25mg weekly — and notice very little. No dramatic appetite suppression. Maybe mild nausea. It can feel like the medication isn't working. It is working, just not yet in the way you'll eventually notice: the starting dose exists to let your gastrointestinal system acclimate before the dose escalates to the levels that produce the therapeutic effect.

The standard titration for Wegovy (semaglutide) runs approximately 16–20 weeks to reach the maintenance dose of 2.4mg weekly: four weeks at 0.25mg, four weeks at 0.5mg, four weeks at 1mg, four weeks at 1.7mg, then 2.4mg as the ongoing maintenance dose. Tirzepatide (Zepbound) starts at 2.5mg weekly and escalates every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, up to 15mg.

The temptation to accelerate this schedule is common and understandable. The evidence strongly supports not doing it. The dose escalation timeline exists because each step up carries increased risk of GI side effects. Providers who allow accelerated titration report significantly higher dropout rates due to side effects — people who would have tolerated the medication fine on the standard schedule stop because they escalated too fast and had a bad experience.

What treatment actually feels like, week by week

Weeks 1–4 are mostly about adjustment.

The 0.25mg starting dose produces minimal appetite suppression for most people. What it does produce is the introduction of a new signal to your GI system. Some people experience mild nausea, particularly in the 24–48 hours after an injection. Others feel nothing at all. Either is normal. The key instruction at this stage is consistent injection timing — same day each week — and staying well hydrated.

Weeks 4–12 bring the shift most people describe as the central experience of GLP-1 treatment. As the dose escalates into the 0.5mg and 1mg range, appetite changes in a qualitatively different way than caloric restriction produces. People commonly describe eating half a meal and feeling genuinely satisfied in a way they haven't experienced before. Food noise — the constant low-level thinking about food that characterizes obesity for many people — quiets meaningfully. This is the GLP-1 receptor signaling in the hypothalamus working as intended.

Week 12 and beyond is typically when weight loss becomes clearly visible on the scale. This is not because the drug suddenly becomes more effective — it is because the cumulative effect of weeks of eating less has compounded. The metabolic shift that was building in weeks 4–12 is now visible as pounds lost.

One pattern that consistently surprises first-time patients: the appetite suppression does not feel like willpower. It feels like the desire to eat has simply decreased. This distinction matters because willpower-based approaches to weight loss fail at high rates precisely because they require sustained mental effort against a biological signal. GLP-1 treatment reduces the strength of that signal rather than asking you to override it.

How long treatment lasts

GLP-1 treatment is ongoing, not finite.

This is the most important thing to understand before starting, because it reframes the entire enterprise. The goal is not to take the medication for six months, hit a target weight, and stop. Major clinical guidelines now classify obesity as a chronic metabolic condition — similar to hypertension or type 2 diabetes — requiring long-term management rather than a course of treatment.

The data behind this classification is stark. In the STEP 1 Extension study, participants who stopped semaglutide after 68 weeks regained an average of 11.6% of their body weight within the following year — about two-thirds of the weight they had lost. Similar patterns appear across the tirzepatide trial data. The weight does not stay off when the medication stops because the medication is managing the underlying hormonal and metabolic dysfunction, not curing it.

This is not a failure of the drug. It is the drug working exactly as it was designed to work — managing a chronic condition while you're taking it, just as a blood pressure medication manages hypertension while you're taking it. The expectation that weight loss drugs should produce permanent results without continued treatment comes from the historical framing of weight management as a behavioral problem rather than a metabolic one. The science has moved on from that framing.

Access routes in 2026

Three main paths exist for getting into GLP-1 treatment.

The first is an obesity medicine specialist — a physician with specific training and board certification in obesity management. These providers offer the most specialized care and are best positioned to manage complex cases with multiple comorbidities. The limitation is availability: there are approximately 7,000 board-certified obesity medicine physicians in the United States, covering a country of 330 million people.

The second is your primary care physician. Most PCPs can and do prescribe GLP-1 medications; prescribing rates in primary care have increased sharply as these drugs have moved into mainstream practice. The relationship with your PCP also has the advantage of continuity — they know your full history and can manage GLP-1 therapy alongside your other health conditions.

The third is telehealth, which has become the fastest and in many cases the most cost-efficient route. Telehealth platforms specializing in obesity treatment can get you from initial consultation to prescription within a single week. Many bundle the consultation fee with the medication cost in a monthly subscription that competes favorably with the retail price of the drug alone.

The honest limitation: insurance is a real barrier

Coverage is inconsistent, and that inconsistency is not random.

Commercial insurance plans vary widely in whether they cover GLP-1 medications for obesity versus type 2 diabetes. As of 2026, Medicare covers Wegovy and Zepbound for cardiovascular disease prevention (following the FLOW and SELECT trial data), but coverage for weight loss alone through Medicare remains limited. Many employer-sponsored commercial plans have added GLP-1 coverage, but many have not.

Prior authorization (PA) is required for most GLP-1 prescriptions. PA means your physician must submit documentation to your insurer — typically including your BMI, documented comorbidities, and a history of prior weight loss attempts — before the insurer approves coverage. This process takes anywhere from a few days to several weeks, and initial denial rates run between 20–40% depending on the plan and the drug.

If your claim is denied, the next step is a peer-to-peer review where your physician argues the case directly to the insurance company's medical reviewer. Approval rates on appeal are significantly higher than initial approval rates. Having a thorough PA from the start — and a provider experienced in submitting them — makes a meaningful difference.

Regular monitoring during treatment

Treatment doesn't end with the first prescription.

Most providers schedule check-ins at 4 weeks, 12 weeks, and then quarterly once you reach a maintenance dose. These visits typically include weight measurement, blood pressure, and a review of any side effects. Labs are usually rechecked at the 3-month mark — metabolic panel and A1c at minimum — and annually thereafter if stable. Thyroid labs may be repeated if there was any baseline abnormality.

These follow-ups are not bureaucratic overhead. They are how your provider assesses whether the medication is working, whether you need a dose adjustment, and whether any emerging issues need attention before they become problems. People who stay in regular contact with their provider throughout titration have better outcomes and lower dropout rates than those who fill the prescription and go silent.

Frequently Asked Questions

Can I get a GLP-1 prescription if I don't have diabetes?
Yes. Wegovy (semaglutide 2.4mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3mg) are all FDA-approved specifically for weight management — not diabetes. A BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, qualifies you without any diabetes diagnosis.

How long before I see results?
Most people notice appetite changes in weeks 4–8 as the dose escalates. Visible weight loss on the scale typically begins in weeks 8–12. The most significant weight loss phase usually happens between months 3–9 on the maintenance dose. Results continue beyond that but at a slower rate.

What happens if I have to stop treatment due to cost or insurance?
Weight regain is the likely outcome — on average 60–70% of lost weight returns within 1–2 years. This is not unique to GLP-1 drugs; it mirrors what happens when any effective treatment for a chronic condition is discontinued. The approach in that situation is typically to explore every available savings option before stopping, including manufacturer assistance programs, telehealth bundled pricing, and prior authorization appeals.

Is there a maximum dose, or can the dose keep going up?
Each drug has an FDA-approved maximum dose. For Wegovy (semaglutide) that is 2.4mg weekly. For Zepbound (tirzepatide) it is 15mg weekly. These are the maintenance doses used in clinical trials and the doses at which the efficacy and safety data were established. Going above approved doses is not clinically standard.

Is GLP-1 treatment the same as bariatric surgery?
No. Bariatric surgery physically alters the anatomy of the stomach and sometimes the intestine. GLP-1 treatment is pharmacological — it works through hormonal signaling. The two approaches can actually be used together in some cases. GLP-1 therapy generally produces less weight loss than bariatric surgery on average, though the gap has narrowed considerably with high-dose tirzepatide. The reversibility of GLP-1 treatment is a key practical difference.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.